FRI0401 EFFECT OF LONG-TERM TREATMENT WITH SECUKINUMAB ON LIPID PROFILE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: POOLED 4 YEAR ANALYSIS

Abstract

Background Systemic inflammation may adversely affect the lipid profile in AS and PsA patients (pts)1. Treatment with some TNF and JAK inhibitors have reported increased total cholesterol (TC) and triglycerides (TG) despite reduction in inflammation2-3. Secukinumab (SEC), a fully human monoclonal antibody that directly inhibits IL-17A, has demonstrated a sustained efficacy and consistent safety profile in pts with AS and PsA4 Objectives To evaluate the long-term effect of SEC on key lipid parameters in AS and PsA pts from pooled phase 3 clinical trials, through 208 weeks (wks) Methods This post hoc analysis included pooled data from MEASURE 1-4 (SEC 150 mg) in AS (N = 892) and FUTURE 2-5 studies (SEC 150/300 mg) in PsA (N = 2049), from pts treated with SEC or placebo (PBO). Serum TC, TG, LDL- and HDL-cholesterol and TC/HDL-C levels were assessed at baseline (BL), Wks 16, 104 and 208 in overall population and in sub-groups by prior anti-TNF therapy, concomitant methotrexate (MTX) and BL statin usage. Shift of common terminology criteria for adverse events (CTCAE) grade from BL through Wk 208 were also analysed Results BL characteristics were comparable across SEC and PBO groups. Lipid levels were stable in SEC treated AS and PsA pts through Wk 208 (Table) with mean change (mmol/L) from BL in AS: TC = ±0.1, TG = 0.1-0.2, LDL-C = ±0.1, HDL-C = ±0.04 and TC/HDL-C = ±0.2 and PsA: TC = ±0.2, TG = 0.001-0.2, LDL-C = ±0.2, HDL-C = ±0.06 and TC/HDL-C = ±0.2. Stable lipid values were also seen across key sub-groups by prior anti-TNF therapy, concomitant MTX and BL statin usage, which remained stable through Wk 208. No Change in CTCAE lipid grades was observed in >90% of SEC-treated pts through Wk 208 Conclusion SEC did not adversely affect the lipid profile and TC/HDL-C ratio in pts with AS and PsA, over 4 years. The lipid profile remained stable with SEC treatment and was sustained irrespective of prior anti-TNF status, concomitant MTX and BL statin usage References [1] Papagoras C, et al. Joint Bone Spine2014;81:57-63 [2] Wolk R, et al. J Clin Lipidol.. 2017;11:1243-56 [3] Agca R, et al. J Rheumatol. 2017; 44(9):1362-8 [4] Lubrano E and Perrotta FM. Ther Clin Risk Manag. 2016;12:1587-92 Disclosure of Interests Iain McInnes Grant/research support from: AstraZeneca, Celgene, Compugen, Novartis, Roche, UCB Pharma, Consultant for: AbbVie, Celgene, Galvani, Lilly, Novartis, Pfizer, UCB Pharma, Dafna D Gladman Grant/research support from: AbbVie, Amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB, Atul Deodhar Grant/research support from: AbbVie, Amgen, Eli Lilly, GSK, Janssen, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Corinne Miceli Richard Grant/research support from: MSD, Pfizer, AbbVie, Biogen, UCB, Novartis, Consultant for: Abbvie, Novartis, BMS, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Abhijit Shete Shareholder of: Novartis Pharma AG, Employee of: Novartis Pharma AG, Daren Asquith Shareholder of: Novartis Pharma AG, Employee of: Novartis Pharma AG, Hanno Richards Shareholder of: Novartis Pharma AG, Employee of: Novartis Pharma AG, Luminita Pricop Shareholder of: Novartis, Employee of: Novartis, Jianyuan Wang Employee of: Novartis